Privi Speciality Chemicals Limited share price
NSE: PRIVISCL · ISIN INE959A01019
Key numbers
- Market cap
- ₹ 14,040 Cr
- Current price
- ₹ 3,594.10
- 52-week high / low
- ₹ 3,785 / 2,340
- Stock P/E
- 41.4
- Book value
- ₹ 361.6
- Dividend yield
- 0.28%
- ROCE
- 22.3%
- ROE
- 26.0%
- Debt to equity
- 0.72
- Sales growth (3 yrs)
- 16.6%
- Profit growth (3 yrs)
- 145.2%
- 1-year return
- 48.3%
About Privi Speciality Chemicals Limited
Privi Speciality Chemicals Limited, together with its subsidiaries, manufactures, supplies, and trades in aroma and fragrance chemicals in India and internationally. The company offers aroma chemicals, including alpha damascone, alpha ionone, alpha terpenyl acetate, amber fleur, amber gamma, ambery woody extreme, beta iso damascol, bi perfumery and technical grades, camphor, carene, carvacrol, cedar ketol, cineole, citronellal, citronellol, citronellyl acetate and nitrile, cyclademol, cyclamen aldehyde, dipentene, double distilled turpentine oil, dihydro myrcenol, dihydromyrcene, eucalyptol, floravone, galaxmusk, gamma methyl ionone, gamma terpenyl acetate, geraniol, and geranyl acetate. It also provides Indian sandal core, indomeran, ionone, iso borneol commercial, iso boronyl acetate, isobornyl cyclohexanol, l-limonene, methyl ionone, nerol, neryl acetate, nimberol, OTBCHA, pine oil, prionyl, PTCBH, PTBCHA, rose oxide, sandal fleur, terpeniol alpha, terpeniol gamma, terpeniol BP grade, terpinolene, tetrahydroflorol, tetrahydrogeraniol, tetrahydrogeranyl acetate, tetrahydromyrcenol, and timber forte and touch. The company's products are used in home care, personal care,…
Quarterly results
Consolidated figures in ₹ crores
| Mar 2025 | Jun 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|
| Sales | 614 | 559 | 605 | 722 | 666 |
| Operating profit | 133 | 132 | 151 | 180 | 152 |
| Net profit | 67 | 62 | 78 | 94 | 84 |
| EPS (₹) | 17.03 | 15.85 | 19.97 | 23.99 | 21.56 |
Concall summary (2026-08-03)
AI summary of the earnings call transcript · tone: Positive · source document
Guidance & outlook
- The EBITDA margins are expected to sustain at a (+20%) driven by the operational efficiencies and improved product mix and increased capacities going to come forward in the near future and in the coming years.
- EBITDA margins were at around 24.58% for the quarter, and we expect, as mentioned, EBITDA margins to be almost similar in the near future.
Growth & demand
- 666 crore, which is reflecting growth of 19.22% year-on-year, supported by healthy demand across both domestic and international markets.
- A 19.22% revenue growth was reported during this quarter on a year-on-year basis comparison.
Margins & costs
- We delivered around 25% margins consistently now across the last nine quarters.
- Privi Speciality Chemicals Limited July 31, 2026 While input costs remain volatile during the quarter, we continue to focus on operational efficiencies, cost optimization initiatives and improved capacity utilization which supported margin resilience.
Capex & expansion
- As Sanjeev mentioned, our Phase-1 of production capacity expansion is progressing as planned and is expected to be commercialized shortly.
- And about the capacity expansion, the current flagship product expansion will happen in the course of the next 15 days or so.
Balance sheet & cash
- I am very happy to inform that due to the excellent management and constant monitoring and focus, we have been able to bring down our overall working capital cycle in this quarter to 108 days during the period as against 141 dats in the previous year.
- Our net debt-to-equity ratio was a very sound healthy 0.57x, reflecting good generation of profit.
Peers in Specialty Chemicals
Data for information only, not investment advice. Prices end of day.